Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Product Development

Eisai’s new data provide insight into how to get the most out of anti-amyloid mAbs

Three-year Leqembi readout in tau subgroup may be most impressive amyloid mAb data to date

July 30, 2024 11:43 PM UTC

It’s early days for precision medicine in neuroscience, but in Alzheimer’s disease, biomarkers that can identify a patient’s stage of disease are indicating the huge value they might bring. New data for Leqembi lecanemab from Eisai using tau PET imaging show that in certain early-stage patients, anti-amyloid therapy can not just slow but reverse cognitive decline, for at least three years. The ability to identify super-responders helps counter the narrative that the antibody has only modest efficacy. 

The data are arguably the most striking efficacy results from an amyloid mAb to date, with a very meaningful benefit for patients, albeit in a small, though well-defined, population of patients with no or very little tau pathology in the brain. These findings should put to rest any lingering questions about whether targeting amyloid can be effective. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article